A Diagnostic Study of CD38-Targeted ImmunoPET of Myeloma

ClinicalTrials.gov ID: NCT04814615

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT04814615. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:03 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Diagnostic Study of CD38-Targeted ImmunoPET of Myeloma: Phase 2 Trial of Clinical Applications

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Evaluation of myeloma disease burden is currently suboptimal. This limits treatment planning and evaluation of residual disease following treatment. 89Zr-DFO-daratumumab is a novel immunoPET tracer, designed to detect CD38 on myeloma cells and allow visualization of myeloma in a PET scanner. A phase I study of 89Zr-DFO-daratumumab demonstrated safety and successful visualization of myeloma with 89Zr-DFO-daratumumab. This will be a phase II study of 89Zr-DFO-daratumumab to evaluate potential clinical applications of this novel imaging agent.

Study identification

NCT ID: NCT04814615
Recruitment status: Not listed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Hoag Memorial Hospital Presbyterian; Other
Enrollment: 60 participants

Conditions and interventions

Conditions

Multiple Myeloma

Interventions

89Zr-daratumumab PET/CT Drug

Drug

Eligibility (public fields only)

Age range: 21 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Mar 8, 2021 (Actual)
Primary completion: Jan 31, 2026 (Estimated)
Completion: Mar 15, 2026 (Estimated)
Last update posted: Jun 27, 2023

2021 – 2026

United States locations

U.S. sites: 2
U.S. states: 2
U.S. cities: 2

Facility	City	State	ZIP	Site status
Hoag Memorial Hospital Presbyterian	Irvine	California	92614	Recruiting
University of Miami	Miami	Florida	33136	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT04814615, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jun 27, 2023 · Synced Nov 15, 2026